Protara Therapeutics, Inc.

NASDAQ:TARA

Biotechnology

Healthcare
$2.34 -1.27%

-$0.05 today

Market cap
$144.07M
Beta
1.45
P/E (TTM)
-2.7
EPS (TTM)
-$1.48
52W Low $2.77High $7.82

Volume 1.15M

Average 0.73M

TARA Other Financing Activities

Financing cash flows not reported separately.

Protara Therapeutics, Inc.NASDAQ: TARA

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities growth accelerates

Q1 FY2026 other financing activities of $272K (cash outflow) rose 47.0% year over year, ahead of the -107.7% change in trailing-twelve-month other financing activities.

Context

  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +47.0% holds above the trailing-twelve-month pace of -107.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$272K— QoQ
Last fiscal yearDec 2025
-$185K-104.8% YoY
LTMMar 2026
-$272K-107.7% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.0%——
1 year-104.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(185K) USD
Year-over-year change
-104.8%

Other Financing Activities vs competitors

How TARA compares with its peers on the latest reported figures

  • TARA's LTM Mar 2026 other financing activities of $272K is the 6th largest of the 10 companies compared; the peer median is $461K.
  • Its year-over-year change of -107.7% is the 7th highest of 9, against a peer median of -71.0%.
TARA Competitors Peer median
Other Financing Activities for TARA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$1.42M -42.0%+149.9%4.1%
MDWDMediWound Ltd.LTM Mar 2026$1.25M -28.5%-18.3%8.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$1.09M -26.8%-46.5%3.3%
OABIOmniAb, Inc.LTM Mar 2026$709K -106.8%—2.5%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$461K +631.7%——
TARAProtara Therapeutics, Inc.LTM Mar 2026$272K -107.7%——
IVVDInvivyd, Inc.LTM Mar 2026$220K -460.7%—0.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$63K -146.7%—0.4%
CDXSCodexis, Inc.LTM Mar 2026$3K -100.0%—0.0%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$0 ———
Peer median (excluding TARA) $461K-71.0%-18.3%2.5%

Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Depreciation & Amortization117K248K341K332K362K
Deferred Income Tax00000
Stock-Based Compensation10.36M6.69M6.09M4.13M3.83M
Change in Working Capital534K539K(4.14M)4.01M(2.94M)
Accounts Receivables00000
Inventory00000
Accounts Payables40K631K848K1.38M(873K)
Other Working Capital494K(92K)(4.99M)2.63M(2.07M)
Other Non-Cash Items1.74M32.02M569K324K(173K)
Operating Cash Flow(34.5M)(26.46M)(37.56M)(35.81M)(56.37M)
Capital Expenditures(596K)(120K)(45K)(63K)(94K)
Acquisitions (Net)97.6K(15.07K)000
Purchases of Investments(124.75M)(43.55M)(12.19M)(29.38M)(204.63M)
Sales of Investments27.15M58.62M65.34M48.6M65.23M
Other Investing Activities(97.6K)15.07K000
Investing Cash Flow(98.19M)14.95M53.11M19.16M(139.49M)
Debt Repayment00000
Common Stock Issued000136.01M82.9M
Common Stock Repurchased(228K)(90K)(91K)00
Dividends Paid00000
Other Financing Activities0003.86M(185K)
Financing Cash Flow(228K)(90K)(91K)139.87M82.72M
Effect of Forex Changes00000
Net Change in Cash(132.92M)(11.6M)15.46M123.21M(113.14M)
Free Cash Flow(35.1M)(26.58M)(37.6M)(35.87M)(56.46M)

Protara Therapeutics, Inc.

NASDAQ:TARA

Intrinsic Alpha fair value

Locked

Current Price

$2.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.